Docetaxel and paclitaxel in the treatment of breast cancer: A review of clinical experience
Docetaxel and paclitaxel in the treatment of breast cancer: A review of clinical experience
复制标题
DOI：
10.1634/theoncologist.9-suppl_2-24
复制
发表时间：
2004-01-01
期刊：
影响因子：
5.8
通讯作者：
Ooi, WS
中科院分区：
文献类型：
--
作者：
Crown, J;O'Leary, M;Ooi, WS
自在欧洲首次获得许可以来的十年间，紫杉烷类药物、紫杉醇和多西紫杉醇已成为治疗乳腺癌的基本药物。具有临床意义的益处首先在转移性环境中显示出来，并且正在对其在早期疾病的辅助治疗中的作用进行大规模探索。在新辅助治疗中也看到了益处，主要是多西紫杉醇。本文综述了紫杉烷类药物目前在转移性和早期乳腺癌治疗中的作用。还解决了涉及最佳剂量和顺序的突出问题，以及在此情况下每种药物的相对优点的讨论。临床医生应根据药代动力学、临床活性和最能满足患者需求的给药方案，为乳腺癌患者选择基于紫杉烷的治疗方案。目前，多西紫杉醇的药代动力学特征、一致的积极临床结果以及间歇性、短时间输注方案的便利性，使多西紫杉醇成为许多治疗乳腺癌患者的临床医生的首选紫杉烷类药物。
In the 10 years since their initial licensing in Europe, the taxanes, paclitaxel and docetaxel, have emerged as fundamental drugs in the treatment of breast cancer. Clinically meaningful benefits were first shown in the metastatic setting, and large-scale exploration of their roles in the adjuvant therapy of early-stage disease is ongoing. Benefits have been seen in the neoadjuvant setting as well, mainly with docetaxel. This paper reviews the current roles of the taxanes in the treatment of metastatic and early-stage breast cancer. Also addressed are outstanding issues involving optimal dosing and sequencing, as well as a discussion of the relative merits of each agent in this setting. Clinicians should choose a taxane-based regimen for their patients with breast cancer based on consideration of the pharmacokinetics, clinical activity, and dosing schedule that best meets the patients' needs. At the current time, the pharmacokinetic profile, consistent positive clinical results, and convenience of an intermittent, short-infusion schedule have made docetaxel the preferred taxane for many clinicians treating patients with breast cancer.